Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.49 HKD | +0.37% | -0.36% | +30.40% |
04-12 | Keymed Biosciences Advances Solid Tumors Drug With First Patient Study | MT |
03-27 | Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+30.40% | 1.16B | - | ||
+2.97% | 108B | B+ | ||
+10.21% | 105B | B+ | ||
+1.57% | 23.46B | B | ||
-12.77% | 21.72B | B+ | ||
-7.05% | 18.64B | A- | ||
-37.64% | 17.45B | A- | ||
-6.50% | 17.19B | B | ||
+6.00% | 13.99B | C+ | ||
+37.20% | 12.53B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2157 Stock
- Ratings Lepu Biopharma Co., Ltd.